OIPE MAIL NOV 22 2006 PATENT & TRADEMARK OFFICE

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-15. (Canceled)

16. (Currently amended) A kit for diagnosing prostate cancer, comprising:

(a) an isolated antibody raised against~~At least one moiety that specifically binds to~~ RM2 antigen, wherein said RM2 antigen comprises~~having~~ the ~~epitope~~ structure shown below~~,~~ ~~from a specimen obtained from a patient suspected of having prostate cancer~~:



wherein R represents a carrier,

(b) instructions~~Instructions~~ for diagnosing prostate cancer using said kit, and

(c) ~~Optionally~~optionally, a means for detecting binding between said antibody and RM2 antigen in a patient sample~~the presence of said antigen by specific binding of said moiety to said antigen~~.

17. (Canceled)

18. (Original) The kit of claim 16, wherein said antibody is selected from the group consisting of a polyclonal antibody, a single chain polyclonal antibody, a polyclonal antibody fragment, a monoclonal antibody, a single chain monoclonal antibody, a monoclonal antibody fragment, a chimeric antibody, a single chain chimeric antibody, a chimeric antibody fragment, a resurfaced antibody, a resurfaced single chain antibody, a resurfaced antibody fragment, a humanized antibody, a humanized single chain antibody, and a humanized antibody fragment.

19. (Canceled).

20. (Currently amended) The kit of claim 16, wherein said antibody~~moiety that specifically binds to said RM2 antigen~~ is a monoclonal antibody.

21. (Currently amended) The kit of claim 16, wherein said antibody raised against said RM2 antigen~~moiety that specifically binds to said RM2 antibody~~ is directed to the epitope recognized by RM2 monoclonal antibody.

22.-33. (Canceled).

34. (New) The kit of claim 16, wherein R is lactosamine chain N-linked or O-linked to glycoprotein, or 4Glcβ1-1Cer in glycosphingolipid.

35. (New) The kit of claim 16, wherein R is a synthetic carrier molecule.

36. (New) The kit of claim 16, wherein R is a naturally-occurring carrier molecule.

37. (New) The kit of claim 16, wherein said RM2 antigen is isolated from a prostate cancer patient.